WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 581759
Description: 2-n-Nonyl-1,3-dioxolane is a biochemical. It is used as an absorption and penetration enhanceron transdermal.
MedKoo Cat#: 581759
Chemical Formula: C12H24O2
Exact Mass: 200.1776
Molecular Weight: 200.32
Elemental Analysis: C, 71.95; H, 12.08; O, 15.97
Synonym: 2-n-Nonyl-1,3-dioxolane; 2-Nonyl-1,3-dioxolane; 2-Nonyldioxolane; AI3-22560; Decanal ethylene acetal.
IUPAC/Chemical Name: 1,3-Dioxolane, 2-nonyl-
InChi Key: QPILHXCDZYWYLQ-UHFFFAOYSA-N
InChi Code: InChI=1S/C12H24O2/c1-2-3-4-5-6-7-8-9-12-13-10-11-14-12/h12H,2-11H2,1H3
SMILES Code: CCCCCCCCCC1OCCO1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 200.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Sha M, Yin LF, Xu W, Chen YZ. [Effects of 2-n-nonyl-1,3-dioxolane as an enhanceron transdermal absorption of Salvia miltiorrhiza gel]. Zhongguo Zhong Yao Za Zhi. 2007 Mar;32(6):487-9. Chinese. PubMed PMID: 17552151.
2: El Maghraby GM, Campbell M, Finnin BC. Mechanisms of action of novel skin penetration enhancers: phospholipid versus skin lipid liposomes. Int J Pharm. 2005 Nov 23;305(1-2):90-104. Epub 2005 Sep 30. PubMed PMID: 16199131.
3: Fuhrman J, Shafer L, Repertinger S, Chan T, Hansen LA. Mechanisms of SEPA 0009-induced tumorigenesis in v-rasHa transgenic Tg.AC mice. Toxicol Pathol. 2005;33(6):623-30. PubMed PMID: 16176921.
4: Usta MF, Sanabria J, Bivalacqua TJ, Hellstrom WJ. Feline penile erection induced by topical glans penis application of combination alprostadil and SEPA (Topiglan). Int J Impot Res. 2004 Feb;16(1):73-7. Erratum in: Int J Impot Res. 2004 Jun;16(3):303.. Sanabriav, J corrected to Sanabria, J. PubMed PMID: 14963475.
5: Hui X, Chan TC, Barbadillo S, Lee C, Maibach HI, Wester RC. Enhanced econazole penetration into human nail by 2-n-nonyl-1,3-dioxolane. J Pharm Sci. 2003 Jan;92(1):142-8. PubMed PMID: 12486690.
6: McVary KT, Polepalle S, Riggi S, Pelham RW. Topical prostaglandin E1 SEPA gel for the treatment of erectile dysfunction. J Urol. 1999 Sep;162(3 Pt 1):726-30; discussion 730-1. PubMed PMID: 10458353.
7: Zhong WZ. Application of solid-phase extraction in the method development for determination of SEPA, an acronym for soft enhancement of percutaneous absorption, in human, rat, and rabbit serum using GC-FID method. J Pharm Biomed Anal. 1998 Mar;16(7):1179-87. PubMed PMID: 9571535.